For patients who have completed up-front docetaxel for metastatic castration-sensitive prostate cancer, should they proceed to abiraterone before the development of castration resistance?
Two recent studies show the benefit of up-front abiraterone for metastatic castration-sensitive prostate cancer, although these studies used control arms of ADT alone rather than ADT + docetaxel. While we await further studies, what will your clinical practice be?
1 Answer
Mednet Member
Medical Oncology · Novant Health Zimmer Cancer Institute
Answered on
There is data for upfront triplet therapy currently in high-volume HSPC. The triplet therapy consists of ADT + docetaxel x 6 cycles + either darolutamide or abiraterone. Given that this patient has already completed a course of docetaxel, holding off on adding ARSI therapy until the first signs of P...
Join for free or sign in to see the full answer